GLPBio

LX1

Catalog No.: GC27918Purity:>99.00%
COASDSData Sheet

LX1 is an anti-prostate cancer compound that targets androgen receptor (AR), AR variants and steroidogenic enzyme AKR1C3.

Los productos son exclusivamente para uso en investigación. No aptos para uso humano. No vendemos a pacientes.

LX1
Cas No.: 2647877-84-5
10mM (in 1mL DMSO)In Stock
$149.00
1
5mgIn Stock
$135.00
1
10mgIn Stock
$225.00
1
25mgIn Stock
$495.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Citas (Citations)

Actualmente no hay citas disponibles para este producto. A continuación se muestran publicaciones seleccionadas que citan productos GlpBio.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Descripción (Description)

LX1 is an anti-prostate cancer compound that targets androgen receptor (AR), AR variants and steroidogenic enzyme AKR1C3. LX1 inhibits the enzymatic activity of AKR1C3, reduces the conversion of androstenedione to testosterone and reduces the expression of AR and AR-V7 and downregulates their target genes. LX1 overcomes the resistance of tumor cells to Enzalutamide, and the combination with Enzalutamide further inhibits tumor growth[1].

References:
[1]. Shu Ning, et al. "LX1 Targets Androgen Receptor Variants and AKR1C3 to overcome Therapy Resistance in Advanced Prostate Cancer." Cancer Research (2024).

Documentos del producto (Product Documents)

Purity:>99.00%Appearance:A solid
COASDSData Sheet

Propiedades químicas (Chemical Properties)

N.º CAS
2647877-84-5
Nombre químico
Benzamide, N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-(phenylmethyl)-
SMILES
O=C(NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)C2=C(O)C=CC(CC3=CC=CC=C3)=C2
Fórmula molecular
C22H15F6NO2
Peso molecular
439.35
Solubilidad
DMSO : 100 mg/mL (227.61 mM; Need ultrasonic)
Almacenamiento
-20°C
Condiciones de envío
Las muestras de evaluación se envían con acumuladores de frío. Los demás tamaños se envían a temperatura ambiente o, previa solicitud, con acumuladores de frío.

Calculadoras (Calculators)Molaridad / Dilución / Peso molecular / Conversión de unidades / Formulación in vivo / Solubilidad

g/mol

Reviews

Review for LX1

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%